Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Alphabet (Google) Class A
GOOGL
|
$498M |
| 2 |
Micron Technology
MU
|
$374M |
| 3 |
Amazon
AMZN
|
$356M |
| 4 |
Accenture
ACN
|
$318M |
| 5 |
Advanced Micro Devices
AMD
|
$301M |
Top Sells
| 1 |
Apple
AAPL
|
$684M |
| 2 |
Meta Platforms (Facebook)
META
|
$630M |
| 3 |
Chevron
CVX
|
$497M |
| 4 |
Shopify
SHOP
|
$439M |
| 5 |
PepsiCo
PEP
|
$375M |
Sector Composition
| 1 | Healthcare | 19.38% |
| 2 | Technology | 18.55% |
| 3 | Consumer Staples | 10.17% |
| 4 | Consumer Discretionary | 9.68% |
| 5 | Financials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Chevron
CVX
$318B
| $334M | 0.47% |
2,325,393
-3,460,902
| -60% | -$497M |
|
27
Eli Lilly
LLY
$658B
| $328M | 0.46% |
1,014,647
+613,764
| +153% | +$198M |
|
28
Incyte
INCY
$16.9B
| $323M | 0.46% |
4,847,233
-295,500
| -6% | -$19.7M |
|
|
29
Accenture
ACN
$158B
| $318M | 0.45% |
+1,237,100
| New | +$318M |
|
30
AstraZeneca
AZN
$254B
| $318M | 0.45% |
5,799,572
-59,500
| -1% | -$3.26M |
|
31
Nike
NKE
$111B
| $314M | 0.44% |
3,781,000
+1,698,312
| +82% | +$141M |
|
|
ABMD
32
DELISTED
Abiomed Inc
ABMD
| $311M | 0.44% |
1,265,800
-180,723
| -12% | -$44.4M |
|
33
Biogen
BIIB
$20.8B
| $308M | 0.44% |
1,154,507
-391,500
| -25% | -$105M |
|
34
Colgate-Palmolive
CL
$67.3B
| $289M | 0.41% |
4,109,386
-763,100
| -16% | -$53.6M |
|
35
Li Auto
LI
$24.5B
| $286M | 0.4% |
12,419,600
+6,390,700
| +106% | +$147M |
|
36
General Mills
GIS
$26.4B
| $282M | 0.4% |
3,679,888
-895,700
| -20% | -$68.6M |
|
37
Visa
V
$676B
| $276M | 0.39% |
1,555,600
+1,149,500
| +283% | +$204M |
|
38
CSX Corp
CSX
$59.8B
| $276M | 0.39% |
10,368,500
-1,161,000
| -10% | -$30.9M |
|
39
GSK
GSK
$79.5B
| $275M | 0.39% |
9,354,057
-625,264
| -6% | -$18.4M |
|
40
Palantir
PLTR
$371B
| $269M | 0.38% |
33,130,047
+4,925,900
| +17% | +$40M |
|
41
Broadcom
AVGO
$1.42T
| $264M | 0.37% |
594,996
+485,410
| +443% | +$216M |
|
42
ASML
ASML
$290B
| $256M | 0.36% |
612,681
+463,749
| +311% | +$194M |
|
43
Cboe Global Markets
CBOE
$24.5B
| $253M | 0.36% |
2,151,524
-195,500
| -8% | -$22.9M |
|
44
Exelixis
EXEL
$9.97B
| $251M | 0.36% |
16,030,844
-1,753,093
| -10% | -$27.5M |
|
45
Petrobras
PBR
$78.6B
| $250M | 0.35% |
20,253,100
+15,098,100
| +293% | +$186M |
|
46
Delta Air Lines
DAL
$40.3B
| $247M | 0.35% |
8,815,900
+5,638,800
| +177% | +$158M |
|
47
Vodafone
VOD
$28.2B
| $247M | 0.35% |
21,790,832
-2,122,844
| -9% | -$24.1M |
|
48
Abbott
ABT
$227B
| $244M | 0.35% |
2,524,258
-1,692,245
| -40% | -$164M |
|
49
Novartis
NVS
$248B
| $242M | 0.34% |
3,181,870
-601,500
| -16% | -$45.7M |
|
50
Ulta Beauty
ULTA
$23.9B
| $237M | 0.34% |
590,500
-110,900
| -16% | -$44.5M |
|